Skip to content

Direct Comparison of SVOne Obtained Refraction to Subjective Manifest Refraction

Direct Comparison of SVOne Obtained Refraction to Subjective Manifest Refraction

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03222661
Enrollment
200
Registered
2017-07-19
Start date
2017-09-30
Completion date
2017-11-30
Last updated
2017-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive Errors

Brief summary

The purpose of the study is to compare the final glasses prescription based on refraction obtained with SVOne device to the final prescription obtained via subjective manifest refraction.

Detailed description

Uncorrected refractive error is the leading cause of vision impairment and the second leading cause of blindness worldwide, affecting 1 in 90 individuals (1). In the US population approximately 14 million individuals aged 12 years or older have visual impairment (defined as distance visual acuity of 20/50 or worse), of which more than 11 million individuals (2) could have their vision improved to 20/40 or better with refractive correction. Uncorrected refractive error impacts all aspects of life, including, but not limited to, loss of employment opportunities, inability to care for family, and inability to receive an education. SVOne is smartphone-based autorefractor, powered by wavefront aberrometry, due to its portability and accuracy it presents as an effective and accessible method of detecting refractive error and dispensing spectacles for better vision (3). In this study, for each patient, a single clinician will determine final prescription through manifest refraction, while a different clinician will determine final prescription using SVOne exam protocol. Sphere, cylinder and axis will be converted to power vectors and compared by linear regression analysis.

Interventions

DIAGNOSTIC_TESTRefraction

Refractive error measurement

Sponsors

Smart Vision Labs
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Subjects must be 12 (under 18 with parental consent) years of age and older up to 65 years of age. * No known ocular pathology from previous clinical exams that may limit best corrected visual acuity.

Exclusion criteria

* Refractive error greater than +/- 14.00 diopters, or astigmatism greater than -7.00 diopters. * Known ocular (corneal, lenticular, vitreal, or retinal) pathology that may limit BCVA. * Best corrected visual acuity with spectacles of 20/25 or worse. * Any previous surgical or laser procedures that may limit BCVA * 11 years of age and younger

Design outcomes

Primary

MeasureTime frameDescription
Sphere, cylinder and axis measurement for each patient4 monthsthe outcome includes sphere, cylinder and axis measurement (in diopter) by using both SVOne wave-guided autorefractor and subjective manifest refraction
Comparison of two measurements on the same patient4 monthsthe outcome will include comparison of two sphere, cylinder and axis measurements (in power vectors) for each patient obtained with SVOne wave-guided autorefractor and subjective manifest refraction.

Countries

United States

Contacts

Primary ContactTihomira Petkova, OD, PhD
tihomira.p@me.com832-202-4780

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026